Acceleron Pharma Inc (XLRN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

128 SIDNEY STREET CAMBRIDGE, MA 02139

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Data as of 2021-06-13 09:32:01 -0400
Market Cap8.1 Billion Shares Outstanding60.699 Million Avg 30-day Volume271.615 Thousand
P/E Ratio-45.36088 Dividend Yield0.0 EPS-3.05
Price/Sales66.92 Debt to Equity1.08 EBITDA-175.462 Million
Price to Book Value9.32 Forward PE Enterprise Value6.871 Billion
Total Cash687.249 Million Current Debt49.819 Million Gross Profit112.937 Million
BETA0.82297 52-week High/Low146.15 / 85.58 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from XLRN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 7 8 -12.5% 3 (0.18%) 4 (0.23%) -25.0%
Funds Holding: 250 253 -1.19% 69 (4.07%) 73 (4.24%) -5.48%
13F shares: 52.32 Million 54.107 Million -3.3% 17.036 Million 16.709 Million 1.96%
% Ownership 86.4085 89.8007 -3.78% 28.1358 27.7317 1.46%
New Positions: 34 44 -22.73% 11 15 -26.67%
Increased Positions 80 83 -3.61% 21 22 -4.55%
Closed Positions 31 27 14.81% 14 12 16.67%
Reduced Positions 90 83 8.43% 21 22 -4.55%
Total Calls 257.401 Thousand 153.202 Thousand 68.01% 62 Thousand 11.4 Thousand 443.86%
Total Puts 306.739 Thousand 176.729 Thousand 73.56% 17.7 Thousand 111.203 Thousand -84.08%
PUT/CALL Ratio 1.19 1.15 3.48% 0.29 9.75 -97.03%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XLRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XLRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

7.5 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

7.5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VENESS ADAM M SVP, GENERAL COUNSEL AND SEC.

  • Officer
20,923 2021-06-07 4

MCCOURT THOMAS A

  • Director
6,044 2021-04-19 3

ZAKRZEWSKI JOSEPH S

  • Director
34,499 2021-04-05 3

SMITH KAREN L.

  • Director
19,457 2021-04-05 3

KANGO SUJAY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
54,396 2021-03-02 5

MCLAUGHLIN KEVIN F SVP, CFO AND TREASURER

  • Officer
10,681 2021-01-29 4

KEARNEY TERRENCE C

  • Director
6,749 2021-01-29 2

NADER FRANCOIS

  • Director
6,749 2021-01-29 1

DABLE HABIB J CEO AND PRESIDENT

  • Officer
  • Director
98,450 2021-01-29 3

BACKSTROM JAY T. EVP, RESEARCH AND DEVELOPMENT

  • Officer
20,781 2021-01-29 2

MALIK KEMAL

  • Director
1,622 2021-01-29 1

HITE CHRISTOPHER

  • Director
930 2021-01-29 1

HAMILL LAURA

  • Director
474 2021-01-29 3

CELGENE CORP /DE/

BRISTOL MYERS SQUIBB CO

  • 10% Owner
7,008,510 2020-07-09 2

GEORGE JEAN

  • Director
5,127 2020-01-22 0

QUISEL JOHN D EVP, CHIEF BUSINESS OFFICER

  • Officer
53,316 2020-01-02 0

BRISTOL MYERS SQUIBB CO

  • 10% Owner
6,971,772 2019-11-20 0

KUMAR RAVINDRA SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
86,986 2019-09-10 0

MANIATIS TOM

  • Director
136,731 2019-01-25 0

POPS RICHARD F

  • Director
32,500 2019-01-25 0

ZELDIN ROBERT K EVP & CHIEF MEDICAL OFFICER

  • Officer
19,103 2019-01-25 0

CELGENE CORP /DE/

6,824,685 2019-01-18 2

SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

  • Officer
77,267 2018-04-03 0

ROVALDI CHRISTOPHER SVP, PROGRAM MGMT AND OPS

  • Officer
25,858 2018-04-03 0

ERTEL STEVEN D EVP & CHIEF OPERATING OFFICER

  • Officer
136,977 2017-03-02 0

MCGUIRE TERRANCE

  • Director
1,250 2017-03-02 0

KNOPF JOHN L CEO AND PRESIDENT

  • Officer
  • Director
214,084 2016-11-09 0

KANIA EDWIN M JR

  • Director
0 2015-01-08 0

MCGUIRE TERRANCE

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
2,621,738 2014-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-06-08 18:53:04 -0400 2021-06-07 F 108 $126.69 d 20,923 direct 3.4464 0.1818 5.4778 3 0.0 1

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 M 7,500 $40.61 a 13,544 direct yes -0.139 2.5838 1.8152 7.776 25 -4.7424 13

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 M 7,500 d 0 direct yes

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 S 4,030 $119.36 d 7,387 direct yes -0.139 2.5838 1.8152 7.776 25 -4.7424 13

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 S 200 $121.23 d 6,044 direct yes -0.139 2.5838 1.8152 7.776 25 -4.7424 13

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 S 2,127 $118.39 d 11,417 direct yes -0.139 2.5838 1.8152 7.776 25 -4.7424 13

MCCOURT THOMAS A - Director

2021-04-21 16:46:11 -0400 2021-04-19 S 1,143 $120.16 d 6,244 direct yes -0.139 2.5838 1.8152 7.776 25 -4.7424 13

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ACCELERON PHARMA INC XLRN 2021-06-17 22:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 21:45:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 21:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 20:45:04 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 20:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 19:45:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 19:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 18:45:04 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 18:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 17:45:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 17:15:03 UTC -0.2404 0.2804 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 16:45:03 UTC -0.2106 0.2506 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 16:15:02 UTC -0.2106 0.2506 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 15:45:03 UTC -0.2106 0.2506 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 15:15:03 UTC -0.2106 0.2506 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 14:45:02 UTC -0.21 0.25 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 14:15:03 UTC -0.21 0.25 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 13:45:03 UTC -0.21 0.25 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 13:15:03 UTC -0.21 0.25 1200000
ACCELERON PHARMA INC XLRN 2021-06-17 12:45:02 UTC -0.21 0.25 1200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund XLRN -6.0 shares, $-539.22 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund XLRN -28.0 shares, $-3150.84 2020-09-30 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND XLRN -1449.0 shares, $-167402.97 2021-01-31 N-PORT
Nuveen Investment Trust II- Nuveen Equity Long/Short Fund XLRN -4600.0 shares, $-626336.0 2021-02-28 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund XLRN -325.0 shares, $-44252.0 2021-02-26 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund XLRN -495.0 shares, $-67126.95 2021-03-31 N-PORT
TIFF INVESTMENT PROGRAM- TIFF Multi-Asset Fund XLRN -1273.0 shares, $-172631.53 2021-03-31 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund XLRN -184.0 shares, $-24952.24 2021-03-31 N-PORT
JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund XLRN -2546.0 shares, $-345263.06 2021-03-31 N-PORT

Elevate your investments